Dr. Ryan C. Young, MD
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- Mayo Medical School (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 996
Licensed in Texas since 2015, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: Mayo Medical School
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
TX license Q6384 (first issued 2015; active) -
Retina Specialist (Ophthalmology) Physician
TX license Q6384 (first issued 2015; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Austin Retina Associates PLLC (19 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 996
- Services billed
- 18,687
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 4,740 | 21 |
| Injection, aflibercept, 1 mg | 2,520 | 266 |
| Imaging of retina | 2,101 | 856 |
| Injection of drug into eye | 1,555 | 420 |
| Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 1,133 | 86 |
| Established patient office or other outpatient visit, 20-29 minutes | 803 | 478 |
| Photography of the retina | 526 | 346 |
| Established patient complete exam of visual system | 332 | 321 |
| Injection, ranibizumab, 0.1 mg | 312 | 30 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 270 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Austin, TX | 126 |
| Prednisolone Acetate Other prescribers in Austin, TX | 57 |
| Latanoprost Other prescribers in Austin, TX | 45 |
| Timolol Maleate Other prescribers in Austin, TX | 23 |
| Ketorolac Tromethamine Other prescribers in Austin, TX | 22 |
| Acyclovir Other prescribers in Austin, TX | 12 |
| Dorzolamide Hcl Other prescribers in Austin, TX | 12 |
| Brimonidine Tartrate Other prescribers in Austin, TX | 11 |
| Brimonidine Tartrate-Timolol (brimonidine tartrate/timolol) Other prescribers in Austin, TX | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 17 payments worth $722 in total to this clinician.
| Regeneron Healthcare Solutions, Inc. | $305 |
|---|---|
| Apellis Pharmaceuticals, Inc. | $186 |
| AbbVie Inc. | $54.25 |
| Harrow Eye, LLC | $47.56 |
| Astellas Pharma US Inc | $42.66 |
| Genentech USA, Inc. | $37.60 |
| Mallinckrodt Hospital Products Inc. | $26.81 |
| Ani Pharmaceuticals, Inc. | $21.92 |
| Food and Beverage | $722 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.